NV-5138

DRUG3 trials

Sponsors

Navitor Pharmaceuticals, Inc.

Conditions

Major Depressive DisorderTreatment Resistant Depression

Phase 1

Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression

CompletedNCT03606395

Navitor Pharmaceuticals, Inc.Treatment Resistant Depression

Start: 2018-06-06End: 2019-07-07Updated: 2019-07-09

Phase 2

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

CompletedNCT05066672

Navitor Pharmaceuticals, Inc.Treatment Resistant Depression

Start: 2022-01-18End: 2025-01-21Updated: 2026-04-17

Open-Label of SPN-820 in Adults With Major Depressive Disorder

CompletedNCT06235905

Navitor Pharmaceuticals, Inc.Major Depressive Disorder

Start: 2024-02-15End: 2024-08-18Updated: 2025-10-21

Related Papers

A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138.

2026-01-07